Basit öğe kaydını göster

dc.contributor.authorMacfarlane, G. J.
dc.contributor.authorKronisch, C.
dc.contributor.authorDean, L. E.
dc.contributor.authorAtzeni, F.
dc.contributor.authorHaeuser, W.
dc.contributor.authorFluss, E.
dc.contributor.authorChoy, E.
dc.contributor.authorKosek, E.
dc.contributor.authorAmris, K.
dc.contributor.authorBranco, J.
dc.contributor.authorDincer, F.
dc.contributor.authorLeino-Arjas, P.
dc.contributor.authorLongley, K.
dc.contributor.authorMcCarthy, G. M.
dc.contributor.authorMakri, S.
dc.contributor.authorPerrot, S.
dc.contributor.authorSarzi-Puttini, P.
dc.contributor.authorTaylor, A.
dc.contributor.authorJones, G. T.
dc.date.accessioned2019-12-10T10:36:43Z
dc.date.available2019-12-10T10:36:43Z
dc.date.issued2017
dc.identifier.issn0003-4967
dc.identifier.urihttps://doi.org/10.1136/annrheumdis-2016-209724
dc.identifier.urihttp://hdl.handle.net/11655/13965
dc.description.abstractObjective The original European League Against Rheumatism recommendations for managing fibromyalgia assessed evidence up to 2005. The paucity of studies meant that most recommendations were ' expert opinion'. Methods A multidisciplinary group from 12 countries assessed evidence with a focus on systematic reviews and meta-analyses concerned with pharmacological/nonpharmacological management for fibromyalgia. A review, in May 2015, identified eligible publications and key outcomes assessed were pain, fatigue, sleep and daily functioning. The Grading of Recommendations Assessment, Development and Evaluation system was used for making recommendations. Results 2979 titles were identified: from these 275 full papers were selected for review and 107 reviews (and/or meta-analyses) evaluated as eligible. Based on metaanalyses, the only ' strong for' therapy-based recommendation in the guidelines was exercise. Based on expert opinion, a graduated approach, the following four main stages are suggested underpinned by shared decision-making with patients. Initial management should involve patient education and focus on nonpharmacological therapies. In case of non-response, further therapies (all of which were evaluated as ' weak for' based on meta-analyses) should be tailored to the specific needs of the individual and may involve psychological therapies (for mood disorders and unhelpful coping strategies), pharmacotherapy (for severe pain or sleep disturbance) and/or a multimodal rehabilitation programme (for severe disability). Conclusions These recommendations are underpinned by high-quality reviews and meta-analyses. The size of effect for most treatments is relatively modest. We propose research priorities clarifying who will benefit from specific interventions, their effect in combination and organisation of healthcare systems to optimise outcome.
dc.language.isoen
dc.publisherBMJ
dc.relation.isversionof10.1136/annrheumdis-2016-209724
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatology
dc.titleEular Revised Recommendations For The Management Of Fibromyalgia
dc.typeinfo:eu-repo/semantics/review
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAnnals Of The Rheumatic Diseases
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları
dc.identifier.volume76
dc.identifier.issue2
dc.identifier.startpage318
dc.identifier.endpage328
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster